Acutus Medical Inc (AFIB)

$0.06 -0.03 (-33.89%)
Market Cap 2.68M
Revenue (ttm) 7.16M
Net Income (ttm) -81.66M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,869,100
Avg Vol 801,830
Day's Range N/A - N/A
Shares Out 29.72M
Stochastic %K 7%
Beta 0.25
Analysts Strong Buy
Price Target $1.50

Company Profile

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is h...

Industry: Medical Devices
Sector: Healthcare
Phone: 442 232 6080
Fax: 442 232 6081
Address:
2210 Faraday Avenue, Suite 100, Carlsbad, United States
Pawsvesting
Pawsvesting Sep. 26 at 6:38 PM
$AFIB no trades since 9/19 as per Fidelity.
1 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 1:22 PM
$AFIB Based on available data, the ownership breakdown for AFIB stock (Acutus Medical, Inc.) is as follows: ​Insiders: Approximately 19.61% of the stock is owned by insiders. This includes individuals and entities with a significant stake in the company, such as corporate officers, board members, and 10% shareholders. ​Institutions: Institutional ownership is reported to be very low, at approximately 0.00706%.
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 1:12 PM
$AFIB In summery, Given their contract with Medtronic is up to January 2027 And the company has annunced that they are Fully founded till then, And the fact that IMHO the company is buying Back their own shares QUIETLY! I see no reason to panic! Worse case, A CLASS ACTION WILL BE IN ORDER TO GET THEM TO COME CLEAN! We still have time for that. ME LIKES😁
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 1:06 PM
$AFIB ​Cost of the System: While not the sale price of the company, the cost to a hospital or clinic for a new 3D cardiac mapping system can provide a benchmark. A typical 3D cardiac mapping system can cost anywhere from $150,000 to $500,000, excluding the cost of the single-use catheters used for each procedure. ​Conclusion ​While the market for electrophysiology mapping systems is in the billions of dollars and a single system can cost hundreds of thousands, it's impossible to determine the exact sale price of the AcQMap platform without a public announcement from the companies involved. The valuation is a result of a negotiation based on the technology's strategic value, the competitive landscape, and the financial circumstances of the companies involved!!!! Hmmmm..........
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 1:04 PM
$AFIB Factors that Influence Valuation ​The "customary valuation" for an electrophysiology mapping system like the AcQMap is not a single price but a range influenced by several factors, including: ​Market Size: The overall cardiac mapping and electrophysiology market is large and growing. Recent reports indicate the global cardiac mapping market was valued at around $2.62 billion in 2025 and is projected to reach over $6.5 billion by 2034. The potential of a product to capture a share of this market is a key driver of its value. ​System Capabilities and Technology: The AcQMap system is a high-resolution, non-contact mapping system, which distinguishes it from some conventional systems. Its unique technology and clinical data on its effectiveness (such as the RECOVER AF study results) would be a primary valuation driver.
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 12:54 PM
$AFIB Sale of Electrophysiology Assets to EnChannel ​What was sold: More recently, in a separate deal, Acutus Medical has also entered into an agreement to sell its AcQMap platform assets to EnChannel Medical. This deal was announced in July 2025. ​The Deal: This agreement includes the high-resolution imaging and mapping platform (AcQMap), intellectual property, and clinical data. The deal is intended to allow Acutus to exit the electrophysiology mapping and ablation business entirely. ​Status: This sale was agreed upon in July 2025. This transaction appears to be a definitive step for Acutus to focus on its remaining obligations to Medtronic and its new business model as a contract manufacturer.
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 12:51 PM
$AFIB Those analyses must know some things That we dont!! Because of lack of information disiminated By the company, Its hard to rely on their analysis! One thing for sure. Given that the company Is selling DOOR KNUBS and all, I am sure that They are talking to some snalysits to make A case for their valuation! Totally against the REG FD!! Oh well, THEY DON'T have to follow the SEC rules!!😆😆😅😅🤣😂😂😂🤣🤣😅 The SEC allows a company to keep material events a secret!!!! (TOTALLY UN AMERICAN) NOT ANNUNCING THE TERMS OF THE SALE OF THEIR ACQ, IS AN EXAMPLE! AFIB is opperating like a Chinese company! 😁😆😅😅🤣😂😂😂🤣😅😅😆😆😁😁 No fortune cockies for you!!
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 12:39 PM
$AFIB PPS recent Projection, Price Targets ​Average Price Target: The average price target set by analysts is reported to be around $12.60. ​Low Analyst Coverage: It is crucial to understand that a low number of analysts are covering this stock, and the targets provided are their own projections and not a guarantee of future performance.
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 12:37 PM
$AFIB Analyst Consensus and Ratings ​Consensus Rating: The general consensus from a small number of analysts is a "Buy" rating for AFIB. ​Breakdown of Ratings: ​Strong Buy: 40% of analysts. ​Hold: 60% of analysts. ​Sell: 0% of analysts. ​Divergent Opinions: It's important to note that the number of analysts covering AFIB is very small, and their opinions can be highly divergent. For instance, a report from July 2025 showed that 100% of analysts giving a rating had a "Sell" recommendation, which has since shifted to the current "Buy" and "Hold" mix.
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 12 at 2:25 PM
$AFIB They are hard at work making us money. Me likes!😁 Call and find out for yourself. (442)232-6080
2 · Reply
Latest News on AFIB
No data available.
Pawsvesting
Pawsvesting Sep. 26 at 6:38 PM
$AFIB no trades since 9/19 as per Fidelity.
1 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 1:22 PM
$AFIB Based on available data, the ownership breakdown for AFIB stock (Acutus Medical, Inc.) is as follows: ​Insiders: Approximately 19.61% of the stock is owned by insiders. This includes individuals and entities with a significant stake in the company, such as corporate officers, board members, and 10% shareholders. ​Institutions: Institutional ownership is reported to be very low, at approximately 0.00706%.
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 1:12 PM
$AFIB In summery, Given their contract with Medtronic is up to January 2027 And the company has annunced that they are Fully founded till then, And the fact that IMHO the company is buying Back their own shares QUIETLY! I see no reason to panic! Worse case, A CLASS ACTION WILL BE IN ORDER TO GET THEM TO COME CLEAN! We still have time for that. ME LIKES😁
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 1:06 PM
$AFIB ​Cost of the System: While not the sale price of the company, the cost to a hospital or clinic for a new 3D cardiac mapping system can provide a benchmark. A typical 3D cardiac mapping system can cost anywhere from $150,000 to $500,000, excluding the cost of the single-use catheters used for each procedure. ​Conclusion ​While the market for electrophysiology mapping systems is in the billions of dollars and a single system can cost hundreds of thousands, it's impossible to determine the exact sale price of the AcQMap platform without a public announcement from the companies involved. The valuation is a result of a negotiation based on the technology's strategic value, the competitive landscape, and the financial circumstances of the companies involved!!!! Hmmmm..........
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 1:04 PM
$AFIB Factors that Influence Valuation ​The "customary valuation" for an electrophysiology mapping system like the AcQMap is not a single price but a range influenced by several factors, including: ​Market Size: The overall cardiac mapping and electrophysiology market is large and growing. Recent reports indicate the global cardiac mapping market was valued at around $2.62 billion in 2025 and is projected to reach over $6.5 billion by 2034. The potential of a product to capture a share of this market is a key driver of its value. ​System Capabilities and Technology: The AcQMap system is a high-resolution, non-contact mapping system, which distinguishes it from some conventional systems. Its unique technology and clinical data on its effectiveness (such as the RECOVER AF study results) would be a primary valuation driver.
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 12:54 PM
$AFIB Sale of Electrophysiology Assets to EnChannel ​What was sold: More recently, in a separate deal, Acutus Medical has also entered into an agreement to sell its AcQMap platform assets to EnChannel Medical. This deal was announced in July 2025. ​The Deal: This agreement includes the high-resolution imaging and mapping platform (AcQMap), intellectual property, and clinical data. The deal is intended to allow Acutus to exit the electrophysiology mapping and ablation business entirely. ​Status: This sale was agreed upon in July 2025. This transaction appears to be a definitive step for Acutus to focus on its remaining obligations to Medtronic and its new business model as a contract manufacturer.
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 12:51 PM
$AFIB Those analyses must know some things That we dont!! Because of lack of information disiminated By the company, Its hard to rely on their analysis! One thing for sure. Given that the company Is selling DOOR KNUBS and all, I am sure that They are talking to some snalysits to make A case for their valuation! Totally against the REG FD!! Oh well, THEY DON'T have to follow the SEC rules!!😆😆😅😅🤣😂😂😂🤣🤣😅 The SEC allows a company to keep material events a secret!!!! (TOTALLY UN AMERICAN) NOT ANNUNCING THE TERMS OF THE SALE OF THEIR ACQ, IS AN EXAMPLE! AFIB is opperating like a Chinese company! 😁😆😅😅🤣😂😂😂🤣😅😅😆😆😁😁 No fortune cockies for you!!
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 12:39 PM
$AFIB PPS recent Projection, Price Targets ​Average Price Target: The average price target set by analysts is reported to be around $12.60. ​Low Analyst Coverage: It is crucial to understand that a low number of analysts are covering this stock, and the targets provided are their own projections and not a guarantee of future performance.
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 14 at 12:37 PM
$AFIB Analyst Consensus and Ratings ​Consensus Rating: The general consensus from a small number of analysts is a "Buy" rating for AFIB. ​Breakdown of Ratings: ​Strong Buy: 40% of analysts. ​Hold: 60% of analysts. ​Sell: 0% of analysts. ​Divergent Opinions: It's important to note that the number of analysts covering AFIB is very small, and their opinions can be highly divergent. For instance, a report from July 2025 showed that 100% of analysts giving a rating had a "Sell" recommendation, which has since shifted to the current "Buy" and "Hold" mix.
0 · Reply
MrMaxxxx
MrMaxxxx Sep. 12 at 2:25 PM
$AFIB They are hard at work making us money. Me likes!😁 Call and find out for yourself. (442)232-6080
2 · Reply
Robsonic
Robsonic Sep. 12 at 8:49 AM
$AFIB We will probably lose everything as a result of the liquidation. I doubt we will get anything.
1 · Reply
MrMaxxxx
MrMaxxxx Sep. 11 at 3:47 PM
$AFIB https://www.medicaltubingandextrusion.com/acutus-sell-electrophysiology-assets-enchannel/
1 · Reply
MrMaxxxx
MrMaxxxx Sep. 7 at 10:35 PM
$AFIB 2025 is coming to an end soon enough. They need to update us. They sold ACQ and no news release!! Deerfield should have been paid off by now! I wonder what their plans are! They are suppose to return the money to share holders! Lets hope that we dont need to file a class action to get them to come clean! Time will tell, but time is running short for them! Tick Tock Tick Tock
1 · Reply
Pawsvesting
Pawsvesting Sep. 5 at 4:11 PM
$AFIB looking for a tuck-in ol’ geoff
0 · Reply
MrMaxxxx
MrMaxxxx Aug. 11 at 10:40 PM
$AFIB The market cap is less than $15K 😆 🤣 😂
1 · Reply
MrMaxxxx
MrMaxxxx Aug. 10 at 11:47 AM
$AFIB These guys mentioned in one of their fillings that they will have a deal to annunce By end of thr year. End of the year is approching fast. NOT SELLING TILL THE FAT LADY SINGS!
1 · Reply
Pawsvesting
Pawsvesting Aug. 4 at 2:10 PM
$AFIB Well…
2 · Reply
MrMaxxxx
MrMaxxxx Jul. 31 at 3:05 PM
$AFIB Per their last filling, There were 198 Share holders remaining, by the volume Most are still holding! They can not just cancel the shares as They wish, and they dont want to FILE BK, as there is more value here and the case Will be dismissed. They will have to start producing some news. And get the share holders out. This will go to court otherwise. Its just a matter of time before Some attorney files a class action. Its coming.
0 · Reply
Pawsvesting
Pawsvesting Jul. 30 at 2:05 PM
$AFIB No quorum. Someone is not playing nicely in the sandbox.
1 · Reply
Pawsvesting
Pawsvesting Jul. 28 at 4:49 PM
$AFIB Worth repeating: EVERYTHING MEDTRONIC $MDT TOUCHES TURNS TO SHIT.
1 · Reply
Pawsvesting
Pawsvesting Jul. 28 at 4:47 PM
$AFIB Deerfield wants their money and then some.
1 · Reply
Pawsvesting
Pawsvesting Jul. 28 at 3:51 PM
$AFIB Classic skullduggery
0 · Reply